Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma

Journal of Neuro-Oncology

Volumn 103, Issue 1, 2011, Pages 59-69

  Faoro, Denis ^a   Von Bueren, André O ^b   Shalaby, Tarek ^a   Sciuscio, Davide ^c   Hürlimann, Marie Louise ^a   Arnold, Lucia ^a   Gerber, Nicolas U ^a   Haybaeck, Johannes ^d   Mittelbronn, Michel ^e   Rutkowski, Stefan ^b   Hegi, Monika ^c   Grotzer, Michael A ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

Childhood brain tumors; Medulloblastoma; Methylation; MGMT

Indexed keywords

6 O BENZYLGUANINE; BETA ACTIN; LOMUSTINE; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; MEDULLOBLASTOMA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE GENE; NEUROECTODERM TUMOR; OVERALL SURVIVAL; PHARMACOGENETICS; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TUMOR CELL LINE; CELL PROLIFERATION; CEREBELLUM TUMOR; DRUG EFFECT; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; MULTICENTER STUDY (TOPIC); PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; WESTERN BLOTTING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOENZYME TECHNIQUES; LOMUSTINE; MALE; MEDULLOBLASTOMA; MULTICENTER STUDIES AS TOPIC; NEUROECTODERMAL TUMORS, PRIMITIVE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 79959954645     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0366-7     Document Type: Article

References (58)

1. Gurney JG, Smith MA, Bunin GR (2000) CNS and miscellaneous intracranial and intraspinal neoplasms. In: SEER pediatric monograph. National Cancer Institute, pp 51-63. http://seer.cancer. gov/Publications/
2. Packer RJ (1999) Alternative treatments for childhood brain tumors. Childs Nerv Syst 15:789-794
3. Douglas JG, Barker JL, Ellenbogen RG, Geyer JR (2004) Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 58(4):1161-1164 (Pubitemid 38314800)
4. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4(4):296-307 (Pubitemid 38525285)
5. Tano K, Shiota S, Collier J, Foote RS, Mitra S (1990) Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci USA 87(2):686-690
6. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20(9):2388-2399 (Pubitemid 34441669)
7. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50(19):6119-6129 (Pubitemid 20323662)
8. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine- DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59(4): 793-797 (Pubitemid 29086728)
9. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223
10. Gonzaga PE, Brent TP (1989) Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide. Nucleic Acids Res 17(16):6581-6590 (Pubitemid 19215579)
11. Coulondre C, Miller JH (1977) Genetic studies of the lac repressor. IV. Mutagenic specificity in the lacI gene of Escherichia coli. J Mol Biol 117(3):577-606 (Pubitemid 8256693)
12. Aquilina G, Hess P, Branch P, MacGeoch C, Casciano I, Karran P, Bignami M (1994) A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. Proc Natl Acad Sci USA 91(19):8905-8909
13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Caincross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003 (Pubitemid 40349502)
14. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine- DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10(6):1871-1874 (Pubitemid 38375541)
15. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350-1354
16. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol 24(21):3431-3437 (Pubitemid 46638900)
17. He XM, Ostrowski LE, von Wronski MA, Friedman HS, Wikstrand CJ, Bigner SH, Rasheed A, Batra SK, Mitra S, Brent TP (1992) Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines. Cancer Res 52(5):1144-1148
18. Hongeng S, Brent TP, Sanford RA, Li H, LE Kun, Heideman RL (1997) O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin Cancer Res 3(12 Pt 1):2459-2463 (Pubitemid 28133168)
19. Rood BR, Zhang H, Cogen PH (2004) Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro-oncology 6(3):200-207 (Pubitemid 39136503)
20. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P (2004) Microarraybased screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64(9):3103-3111 (Pubitemid 38581410)
21. Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD (2005) O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 11(7):2747-2755 (Pubitemid 40569477)
22. von Bueren AO, Shalaby T, Rajtarova J, Stearns D, Eberhart CG, Helson L, Arcaro A, Grotzer MA (2007) Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 7(1):19
23. Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M (2000) Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcriptionpolymerase chain reaction assay. Clin Cancer Res 6(2):452-459 (Pubitemid 30111463)
24. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25(4):386-401 (Pubitemid 34164011)
25. Mengelle C, Sandres-Saune K, Pasquier C, Rostaing L, Mansuy JM, Marty M, Da Silva I, Attal M, Massip P, Izopet J (2003) Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J Clin Microbiol 41(8):3840-3845 (Pubitemid 36994724)
26. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B, DiGuiseppi J, Bierau K, Hegi ME (2008) Validation of real-time methylation-specific PCR to determine O6-methylguanine- DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10(4):332-337 (Pubitemid 352019119)
27. Mikeska T, Bock C, El-Maarri O, Hübner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Büttner R, Pietsch T, Waha A (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9(3):368-381 (Pubitemid 47305073)
28. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB (2008) Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26(14):2299-2304
29. Ringquist S, Styche A, Rudert WA, Trucco M (2007) Pyrosequencing- based strategies for improved allele typing of human leukocyte antigen loci. Methods Mol Biol 373:115-134
30. Brakensiek K, Wingen LU, Langer F, Kreipe H, Lehmann U (2007) Quantitative high-resolution CpG island mapping with pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem 53(1):17-23 (Pubitemid 46047759)
31. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106(6):2162-2168 (Pubitemid 41291734)
32. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM (2006) Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 94(4):561-568 (Pubitemid 43289761)
33. Liu L, Schwartz S, Davis BM, Gerson SL (2002) Chemotherapyinduced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Cancer Res 62(11):3070-3076 (Pubitemid 34602397)
34. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur CM, Phillips PC (2000) Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19(40):4604-4610
35. Cejka P, Stojic L, Mojas N, Russell AM, Heimimann K, Cannavo E, di Pietro M, Marra G, Jiricny J (2003) Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J 22(9):2245-2254 (Pubitemid 36565547)
36. Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sörensen N, Warmuth-Meth M, Bamberg M (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46(2): 269-279 (Pubitemid 30067775)
37. Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13(9): 2651-2657 (Pubitemid 46788032)
38. Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR (1996) Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2(4):735-741
39. Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME (2002) O6-benzylguaninemediated enhancement of chemotherapy. Mol Cancer Ther 1(11):943-948
40. Bacolod MD, Johnson SP, Pegg AE, Dolan ME, Moschel RC, Bullock NS, Fang Q, Colvin OM, Modrich P, Bigner DD, Friedman HS (2004) Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 3(9):1127-1135 (Pubitemid 39295010)
41. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MB, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189-4199
42. Preusser M, Janzer CR, Felsber J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18(4):520-532
43. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18): 9821-9826 (Pubitemid 26296693)
44. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97(18):1330-1338 (Pubitemid 41487800)
45. Tost J, Gut IG (2007) DNA methylation analysis by pyrosequencing. Nat Protoc 2(9):2265-2275 (Pubitemid 351575045)
46. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20(24):4684-4691 (Pubitemid 36025286)
47. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42(14):2335-2342 (Pubitemid 44316901)
48. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11(4):448-457 (Pubitemid 38489422)
49. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96(3):766-776
50. Lewandowicz GM, Harding B, Harkness W, Hayward R, Thomas DG, Darling JL (2000) Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. Eur J Cancer 36(15):1955-1964
51. Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichigans J, Weller M, Schulz JB (2004) Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 91(5): 1067-1074 (Pubitemid 39587445)
52. Stojic L, Brun R, Jiricny J (2004) Mismatch repair and DNA damage signalling. DNA Repair 3(8-9):1091-1101 (Pubitemid 38997952)
53. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58(19):4363-4367 (Pubitemid 28450038)
54. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH (1992) Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 65(2):287-291
55. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23(1):35-61 (Pubitemid 27273454)
56. Spiro TP, Liu L, Majka S, Haaga J, Willson JL, Gerson SL (2001) Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine- DNA-alkyltransferase. Clin Cancer Res 7(8):2309-2317 (Pubitemid 32751629)
57. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, chapman PB (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22(4):610-616 (Pubitemid 41095063)
58. Ganiere V, Christen G, Bally F, Guillou L, Pica A, de Ribaupierre S, Stupp R (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol 3(6):339-343 (Pubitemid 43871544)